Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sci PharmtechTPE:4119 -3.81%73 Debt-to-EBITDA is 2.88 as of Mar. 2026, which is 157% above its 10-year median of 1.12. GuruFocus rates TPE:4119 with a GF Score™ of 73/100 and a GF Value™ of NT$94.63 (Possible Value Trap). The stock has 10 warning signs investors should review. Among 681 Drug Manufacturers companies, Sci Pharmtech ranks worse than 69.16% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sci Pharmtech's Debt-to-EBITDA or its related term are showing as below:
TPE:4119'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 1.12 Max: 3.09
Current: 3.09
During the past 13 years, the highest Debt-to-EBITDA Ratio of Sci Pharmtech was 3.09. The lowest was 0.00. And the median was 1.12.
TPE:4119's Debt-to-EBITDA is ranked worse than 69.16% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.62
vs TPE:4119: 3.09
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sci Pharmtech Debt-to-EBITDA Related Terms
Sci Pharmtech Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Sci Pharmtech's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sci Pharmtech Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sci Pharmtech's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Sci Pharmtech (TPE:4119) has a Debt-to-EBITDA of 2.88 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sci Pharmtech. This is 157% above median its historical median of 1.12. According to the industry distribution chart, Sci Pharmtech ranks #471 out of 681 companies in the Drug Manufacturers industry, placing it in the top 69.2%.
Is Sci Pharmtech's Debt-to-EBITDA too high?
Sci Pharmtech's current Debt-to-EBITDA of 2.88 is 157% above median its 10-year median of 1.12. The Drug Manufacturers industry median Debt-to-EBITDA is 1.62. Sci Pharmtech's value of 2.88 is 77.8% above this industry median. Based on the distribution chart, Sci Pharmtech ranks #471 out of 681 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sci Pharmtech has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sci Pharmtech's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sci Pharmtech ranks #471 out of 681 companies for Debt-to-EBITDA. This places Sci Pharmtech in the lower half of its industry. The industry median Debt-to-EBITDA is 1.62. Sci Pharmtech's value of 2.88 is 77.8% above this benchmark. While the company's 10-year median is 1.12 vs. the industry median of 1.62, Sci Pharmtech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.62, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sci Pharmtech's current Debt-to-EBITDA of 2.88 is 77.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sci Pharmtech. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sci Pharmtech's current Debt-to-EBITDA is 2.88, which is 157% above median its own 10-year median of 1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sci Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sci Pharmtech (TPE:4119) is currently considered Possible Value Trap. The stock's GF Value™ is NT$94.63, compared to a current price of NT$53.00 — trading 44% below its estimated fair value. The current Debt-to-EBITDA is 2.88, which is 157% above median its 10-year median of 1.12 and 77.8% above the Drug Manufacturers industry median of 1.62. Sci Pharmtech's overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sci Pharmtech (TPE:4119), the current Debt-to-EBITDA is 2.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sci Pharmtech (TPE:4119) Overvalued in 2026?
Based on GuruFocus' analysis, Sci Pharmtech stock appears to be undervalued.
The current stock price of NT$53.00 is trading 44% below its estimated GF Value™ of NT$94.63.
GuruFocus considers Sci Pharmtech to be Possible Value Trap.
Key valuation signals for TPE:4119:
Debt-to-EBITDA: 2.88 (157% above median its 10-year median of 1.12)
GF Value™: NT$94.63 vs. price of NT$53.00 (44% below fair value)
Industry Position: 77.8% above the Drug Manufacturers median (#471 of 681)
No single metric tells the full story. See the TPE:4119 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sales of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, Switzerland, Spain, Belgium, Netherlands, and others.
73GF Score
Get the complete analysis for TPE:4119
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4119 has been successfully added to your 
